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Background: Three-dimensional (3D) whole-liver perfusion magnetic resonance(MR) imaging with parallel imaging, a
novel imaging method to characterize tumor vascularization in vivo, has recently been applied to comprehensively
image perfusion changes in large tumors. Coupled with new perfusion software, this technique enables motion
correction, registration, and evaluation of perfusion MR parameters. The purpose of this study was to assess the feasibility
of 3D whole-liver perfusion MR, for imaging hepatocellular carcinoma (HCC) and colorectal hepatic metastases (CRHM).
Methods: 26 patients with hepatic tumors (10 HCC; 16 CRHM) were subjected to 3D whole-liver perfusion MR with a
temporal resolution of 3.7 seconds. The following estimated perfusion parameters were measured: the volume transfer
constant Ktrans (min-1); the volume (Ve) of extravascular extracellular space (EES) per volume unit of tissue; and the flux
rate constant between EES and plasma Kep (min
-1). Statistical analysis was conducted to investigate inter-observer
characteristics and significance of the measured parameters.
Results: Inter-observer agreement analysis (95% limits of agreement) yielded a mean difference of −0.0048 min-1
(−0.0598 ~ 0.0502) for Ktrans , -0.0630 ml (−0.5405 ~ 0.4145) for Ve, and −0.0031 min
-1 (−0.0771 ~ 0.0709) for Kep
respectively. When comparing images from patients with HCC vs. CRHM, significant differences were seen for the mean
Ktrans (p = 0.017), but not for Ve(p = 0.117) or Kep(p = 0.595).
Conclusion: Herein we show that 3D whole-liver MR perfusion imaging with semi-automatic data analysis is feasible and
enables the reliable quantitative evaluation of the perfusion parameters for HCCs and CRHMs.
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The progression of novel therapeutic strategies for ad-
vanced liver cancer stimulates continued development of
diagnostic tools. Whereas existing imaging techniques
are largely limited to morphological evaluation, perfu-
sion imaging has the potential to provide more comprehen-
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reproduction in any medium, provided the ormodalities have been tested to image liver tumors, including
contrast-enhanced ultrasound [2], computed tomography
(CT) [3,4] and magnetic resonance (MR) imaging [5-7].
Although several of these modalities use contrast injec-
tion, which requires the patient to have adequate renal
function, perfusion MR imaging is noninvasive [5-9]. To
increase applicability and reproducibility of this tech-
nique, Tofts et al. [9] standardized the estimation of kin-
etic parameters derived from perfusion MR data. These
include a) the volume transfer constant (Ktrans [min-1]);
b) the volume (Ve) of extravascular extracellular space
(EES) per volume unit of tissue; and c) the flux rate con-
stant between EES and plasma (Kep [min
-1]). The rate
constant is the ratio of the transfer constant to the EES. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trans/Ve). Currently, the majority of perfusion
MR studies focus on a specific area of tumor, failing to
provide comprehensive evaluation of the tumor as a
whole. However, the recently developed technique of
3D whole-liver perfusion MR imaging, combined with
parallel imaging technique, supports imaging of the
entire liver, depicting overall changes in liver perfusion
as well as tumor-specific flow, which also enables
visualization of hemodynamic interactions between the
tumor and the surrounding liver tissue [5,7]. In
addition, new perfusion software enables registration
and correction of motion, reducing misregistration
and respiratory artifacts, and permitting evaluation of
parameters such as Ktrans, Ve, and Kep.
Herein, we evaluate the inter-observer variation during
semi-automated measurement for three-dimensional
(3D) whole-liver MR perfusion parameters. In addition,
this study specifically addresses the significance of ob-
served differences between perfusion imaging of HCC
and CRHM using this novel technique.
Methods
Patient and tumor characteristics
Twenty-six patients with solid liver lesions were included
in this study, consisting of 10 cases of HCC (7 male, 3
female, aged 45–75 years old [mean age 58.8 years]) and
16 cases of CRHM (11 male, 5 female, aged 48–67 years
old [mean age,61.3 years]). In HCC patients, the diagno-
sis was either histologically confirmed during surgery
(n = 8) or based on dynamic CT findings together with
high serum α-fetoprotein (n = 2). Cirrhosis was con-
firmed in all patients with HCC (Child-Pugh A: 9, B: 1),
either through pathological assessment or clinical and
imaging criteria. Of the 16 CRHM patients, four cases
were histologically confirmed during surgery. Twelve
cases showed significant growth or regression of lesions
at follow-up imaging after the commencement of
chemotherapy (defined as ≥20% diametric growth or
regression, mean time of follow-up 4.2 months with a
range of 2–6 months). All patients were required to
not have received any therapy prior to inclusion. In
each patient, a single lesion was chosen as study target,
which were required to be well demarcated contrast-
enhancing solid masses larger than 1.5 cm in the lon-
gest diameter. This study was approved by the ethics
committee of Zhongshan Hospital, Fudan University
(Approval No:2010-17) in compliance with the Helsinki
Declaration, and written informed consent was obtained
from the patient for publication of this report and any
accompanying images.
Perfusion MR imaging
The patients were asked to fast for 6 hours before im-
aging. Perfusion MR was performed using a 3.0-T systemwith phased-array coils (Verio, Siemens Medical Solutions,
Erlangen, Germany). For T1 map calculation, a dual flip
angle (FA) 3D gradient echo sequence with volumetric
interpolated breath-hold examination.
(VIBE) was performed preceding injection of contrast
material. The following imaging parameters were used:
2.84/1.02 (repetition time msec/echo time msec), 2° and
9° FA, 134 × 256 matrix, 2.5 × 1.5-mm in-plane pixel size,
380 × 333-mm field of view, 20 cm slab thickness resulting
in an interpolated 5-mm section thickness, and 750 Hz/
pixel bandwidth. A parallel imaging technique (R factor
of two) was performed using generalized autocalibrating
partially parallel acquisition. Whole-liver perfusion MR
imaging was performed by VIBE in the coronal plane
using 9° FA. The geometrical and spatial parameters of
the perfusion series match the pre-contrast sequence
(resolution, dimensions, orientation) with a temporal
resolution of 3.7 seconds. The first “breath-hold” lasted
1 scan, which was aligned with the beginning of contrast
material injection to obtain a baseline scan. At the 16th
second, three subsequent “breath-holds” were orches-
trated, each lasting for 5 scans every 8 seconds. Finally,
4 subsequent “breath-holds”, each accounting for 4 scans
were obtained in 12-second intervals, resulting in the
acquisition of a total of 32 scans (Figure 1). All patients
received 0.1 mmol/kg body weight of gadopentetate
dimeglumine, administered intravenously at 5 mL/s
through a cubital or cephalic venous entry, and flushed
with 20 mL 0.9% saline.
Data analysis
MR images were analyzed by using commercially avail-
able software on a separate workstation (Tissue 4D,
Syngo MR B17, Siemens Healthcare) to calculate the
perfusion parameters. Semi-automatic evaluation of hep-
atic tumors was performed by two radiologists experi-
enced in abdominal MR imaging, who separately and
independently evaluated the hepatic tumors. The fol-
lowing algorithm was applied: 1. Motion correction:
selection of the the first volume of the dynamic series
as reference volume. The new motion-corrected series
automatically replaces the original dynamic series;
2. Registration: selection of the first volume in the
dynamic series as reference volume for registration;
3. Curve calculation: calculation of enhancement curves
and segment structures manually by drawing regions of
interest (ROIs) in the dynamic series. The curves are
shown as relative enhancement curves with the first vo-
lume serving as reference. 4. Pre-evaluation: the T1 map
calculation of pre-contrast data is a prerequisite for phar-
macokinetic modeling. It runs automatically when we start
the pre-evaluation blind. T1 fitting is restricted to pixels
with values above the noise level cutoff. Once the T1 map
is calculated, the pre-contrast is replaced; 5. Evaluation:
Figure 1 Perfusion MR images of the liver in a 49-year-old male patient with HCC, which showed classic enhancement features of
hyper-vascularity at arterial phase and washout at portal venous phase and delayed phase by selected time points from
32 measurements.
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the mean curves for the selected ROI label. The two-
compartment Tofts model of arterial input functions
(AIFs) is provided; 6. Results: the ROI functionalities on
the Results blind comply with the functionalities on the
Curve Calculation blind. The setting affects only the
ROIs displayed in parameter images (Figure 2); 7. Export:
export of the results.Statistical analysis
Inter-observer variation for perfusion parameters (Ktrans,
Ve, and Kep) was analyzed using a Bland-Altman plot.
Mann–Whitney test and independent samples t-test were
conducted to analyze the difference in mean parameter
values between HCC vs. CRHM patients. All statistical
analyses were conducted using MedCalc (MedCalc for
Windows, version 9.6.4.0). A p-value of less than 0.05 was
considered significant.Results
Morphological features
The mean overall tumor size was 42.6 mm (range, 15–
96 mm), with a mean of 55.4 mm (range, 31.3-96 mm) for
HCC and 42.7 mm (range, 15–95 mm) for CRHM. On
the arterial phase HCC tumors were either homogenously
(n = 3, 30%) or heterogeneously (n = 7, 70%) hyperintense;
while CRHM were peripherally (n = 7, 43.8%) or heteroge-
neously (n = 9, 56.2%) hyperintense. On portal phase
and delayed phase, HCCs were hypointense (n = 9, 90%)
or isointense (n = 1, 10%); while the CRHM were per-
ipherally (n = 7, 43.8%) or heterogeneously (n = 9, 56.2%)
hyperintense. The enhancement pattern during the
dynamic study revealed that the HCCs showed arter-
ial enhancement with washout (n = 9, 90%) or without
(n = 1, 10%) during the portal or delayed phase. In con-
trast, CRHM displayed either progressive heterogeneous
enhancement (n = 9, 56.2%) or progressive peripheral,
rim-like enhancement (n = 7, 43.8%).
Figure 2 Example of evaluation for perfusion parameter by the Tissue 4D tool. T1 map is automatically calculated by the precontrast
images (upper left),and region of interest(ROI) is drawed covering the tumor on the dynamic contrast phases (upper right), then the time-
intentsity curve is automatically calculated(lower right).Finally the colored-code parametric map of MR perfusion is generated(lower left).
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All hepatic tumors were successfully evaluated using
the software tool. The mean differences and their ana-
lysis using the Bland-Altman plots are summarized in
Table 1. Results of the inter-observer agreement ana-
lyses are also represented graphically by Bland-Altman
plot (Figure 3a-c). Significant differences between HCCs
and CRHM were found for the mean Ktrans as determined
by both readers (p = 0.017), but no significant differences
were found for Ve (p = 0.117) or Kep (p = 0.595). Distribu-
tion of the mean perfusion parameters (Ktrans, Ve, Kep) is





Traditional cross-sectional tumor imaging focuses solely
on tumor morphology. With the introduction of targeted
biological therapies in human trials, morphologic changes
as seen on imaging may lag behind other physiologic re-
sponses that were previously not measurable. Perfusion
MR imaging is a new imaging method that enables
characterization of microvascular structures and perme-
ability in vivo [10,11] and is emerging as a promising
method for monitoring tumor response to treatment
[12]. Imaging the entire liver for perfusion analysis of
a hepatic tumor appears mandatory, given that mostfor HCCs and CRHMs by Bland-Altman plots
95% limits of agreement
Lower limit Upper limit
−0.0598 (−0.0794 to −0.0402) 0.0502 (0.0306 to 0.0698)
−0.0771 (−0.1036 to −0.0507) 0.0710 (0.0446 to 0.0974)
−0.5405 (−0.7109 to −0.3702) 0.4145 (0.2441 to 0.5849)
Figure 3 a-c. Bland-Altman plots showing the difference for Ktrans (Figure 3a), Ve (Figure 3b), Kep (Figure 3c) between the two readers.
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degrees of tumor vascularity, necrosis, or hemorrhage. A
single slice image, as used in one previous study [7], is
therefore suboptimal as representation of the tumor in
its entirety.
Conclusions
The Bland-Altman analysis indicates that the perfusion
parameters (Ktrans, Ve, and Kep), as determined in our
study using semi-automatic measurement software, are
reproducible and accurate. We conclude that the perfu-
sion parameters evaluated by the software were not
significantly influenced by observer experience. The
perfusion MR images of all patients in our study reached
the adequate quality necessary to obtain measurements.Figure 4 Mean and 95% confidence interval for perfusion
parameters (Ktrans,Ve,Kep) for HCCs and CRHMs.Respiratory motion is a major issue in hepatic perfusion
imaging. In our study, all the patients held their breath
during the different phases of MR scans, and image acqui-
sition was undertaken by carefully trained and dedicated
technicians. After motion correction and registration
by the software, the perfusion MR images were free of
motion artifacts and misregistration. Good scanning
technique, careful patient positioning and reproducible
injection technique are important for reproducibility of
perfusion MR evaluation. Galbraith [13] et al. evaluated
16 patients with various tumors who underwent MR
examination within 1 week of each other and assessed
perfusion parameters (Ktrans, Kep, and Ve) using the
Tofts’ model, concluding that Ve had good reproduci-
bility within individuals, whereas Ktrans and Kep were
more variable, but nevertheless could detect changes in
tumors ranging from −14 to +16%, and ±16 or ±17%,
respectively. Ng [4] et al. reported that the rate of re-
producibility of DCE-MRI parameters was in the range
of 10%-20% and is influenced by lesion location, param-
eters being significantly more reproducible in the liver
than in lung tissue.
The transfer constant (Ktrans) is a mathematical func-
tion which describes the relationship between the AIF
and contrast concentration changes occurring in the
voxel [14], which is a parameter related to vessel perme-
ability and tissue blood flow. Our study showed that the
mean values of Ktrans obtained from the HCCs were sig-
nificantly higher than those obtained from CRHM. This
is consistent with findings by Ueda [15] et al., who re-
port that the vascular volume of metastases is generally
smaller than that of HCCs. Tumor angiogenesis may
serve as independent prognostic indicator and has been
shown to predict clinical outcome in patients with lung,
breast and colon cancer [16-18]. Vascular endothelial
growth factor (VEGF) was discovered as a major driver
of tumor angiogenesis. Preclinical studies have shown
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wards a more “mature” or “normal” phenotype. This
“vascular normalization” is characterized by attenuation
of hyperpermeability, increased vascular pericyte cover-
age, decrease in basement membrane abnormality, and
a resultant reduction in tumor hypoxia and interstitial
fluid pressure, which enhances efficiency of drug deliv-
ery [19]. The Ktrans is thought to be uniquely suited to
evaluate this normalization process in tumor vascula-
ture [20]. Hence, a decline in Ktrans after anti-angiogenic
treatment reflects either a drop in vascular permeability,
vessel density, or both [19]. The clinical trial employing
PTK787/ZK 222584 therapy in patients with advanced
colorectal cancer and liver metastases reported a rapid
reduction in Ki (K
trans) within 26 to 33 hours after the
first dose [7]. Similar results have been reported in a
trial that involved HCC patients who received sunitinib
therapy [21]. Because of the ability to differentiate be-
tween HCC and CRHM using the Ktrans value, we pose
that our technique of whole-liver perfusion MR is
uniquely suited to be applied during anti-angiogenic
treatment. In a tumor environment with permeable
vasculature, the Ve parameter serves as a marker for
tumor necrosis, as well as being inversely correlated to
tumor cellularity, which in itself may be an under-
utilized indicator of treatment effect [22]. In our study,
there was no difference in Ve value between HCCs and
CRHM, possibly attributable to the high tumoral con-
tent and similar volumes of extravascular extracellular
space between these tumor types.
The number of patients included into our study was
relatively small. In addition, we did not correlate the MR
perfusion measurements with histopathological findings,
such as microvessel density, and we did not evaluate the
response to anti-angiogenic therapy using perfusion MR
as an imaging biomarker. However, the primary aim of
our study was to assess the feasibility of perfusion im-
aging using 3D whole-liver MR perfusion in malignant
hepatic neoplasms.
Our study suggests that 3D whole-liver MR perfusion
enables relevant evaluation of hemodynamic parameters
and vessel permeability of hepatic tumors with accept-
able inter-observer agreement. These findings demon-
strate the ability of this novel technique to contribute to
the treatment of hepatic malignancies.Abbreviations
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